Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger. The resulting company will continue under the Alumis name at the ...

Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a late-stage clinical biopharma company. The merged company will focus on ...

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on ACELYRIN, INC. (SLRN – Research Report). The company’s shares closed yesterday at $1.90. Leverage the ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement in an all-stock transaction, allowing Alumis to leverage increased financial flexibility and an expanded late-stage ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement for an all-stock transaction, with stockholders of each company owning approximately 55% and 45% of the combined entity ...

Biopharmaceutical companies Alumis and ACELYRIN said Thursday they have agreed to a merger which will see the combined company operate under the Alumis name with the current Alumis executive team.

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock transaction. Alumis and Acelyrin had cash, cash equivalents and ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock ...

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN ...

Alumis and Acelyrin are merging, the biotechnology companies said Thursday afternoon, in an all-stock deal that leaves the combined company with a bigger cash balance and three drugs in clinical ...

SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), currently valued at $388 million and trading near its 52-week low of $6.29, and ACELYRIN, INC. (NASDAQ: SLRN) have entered into a ...